Köş, Fahriye TuğbaHocazade, CemilKöş, MehmetUncu, DoğanKarakaş, EsraDoğan, MutluZengin, Nurullah2020-04-302020-04-3020151513-7368https://dx.doi.org/10.7314/APJCP.2015.16.9.3997https://hdl.handle.net/20.500.12684/106PubMed ID: 25987075Background: Systemic inflammatory response was shown to play an important role in development and progression of many cancer types and different inflammation-based indices were used for determining prognosis. We aimed to investigate the prognostic effects of neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) in patients with non-small cell lung cancer (NSCLC). Materials and Methods: NSCLC patients diagnosed in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR and PNI was calculated before the application of any treatment. Results: A total of 138 patients were included in the study. Patients were divided into two groups according to NLR (<3.24 or ? 3.24) and PNI (<49.5 or ? 49.5). While median overall survival was 37.0 (95% CI 17.5-56.5) months in the group with low NLR, it was calculated as 10.0 (95%CI 5.0-15.0) months in the group with high NLR (p<0.0001). While median overall survival was 7.0 (95%CI 3.5-10.5) months in the group with low PNI, it was calculated as 33.0 (95% CI 15.5-50.4) months in the group with high PNI (p<0.0001). Stage, NLR and PNI levels were evaluated as independent risk factors for overall survival for all patients in multivariate analysis (p<0.0001, p=0.04 and p<0.001, respectively). Conclusions: NLR (?3.24) and PNI (<49.5) at diagnosis is an independent marker of poor outcome in patients with NSCLC. NLR and PNI is an easily measured, reproducible prognostic tests that could be considered in NSCLC patients.en10.7314/APJCP.2015.16.9.3997info:eu-repo/semantics/openAccessLung cancer; Lymphocyte; Neutrophil; Prognosis; Prognostic nutritional indexArticle16939974002Q3